Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. ALNY reported second-quarter 2025 earnings of 32 cents per share, in contrast to the Zacks Consensus Estimate of a loss of 3 cents. The improvement was due to higher revenues from the sale of its lead drug, Amvuttra (vutrisiran). The company reported adjusted earnings of 56 cents in the year-ago quarter.
Alnylam recorded total revenues of $773.7 million in the quarter, which easily surpassed the Zacks Consensus Estimate of $673 million. In the year-ago quarter, total revenues were $659.8. The top line rose 17% year over year on a reported basis and 16% at a constant exchange rate (CER), mainly driven by increased product sales.
Net product revenues were $672.2 million, up 64% year over year on a reported basis and 62% at CER, driven by strong growth in patient demand for Amvuttra, as well as for Givlaari (givosiran) and Oxlumo (lumasiran). ALNY shares jumped 15.4% on Thursday as investors responded positively to the strong financial performance of its marketed drug portfolio.
Net revenues from collaborators were $61.5 million, down 73% from the year-ago quarter, primarily due to a $185 million milestone payment received from Regeneron REGN in the year-ago quarter upon granting REGN an exclusive license to develop, manufacture and commercialize cemdisiran as a monotherapy. Furthermore, Alnylam did not recognize any revenues from Novartis NVS in the reported quarter. ALNY recognizes revenues under its ongoing collaborations with Roche RHHBY.
Alnylam also recognized royalty revenues of $40 million in the reported quarter, up 78% year over year.
ALNY’s Q2 Results in Detail
Onpattro (patisiran) is approved for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The injection recorded sales of $52.5 million in the reported quarter, down 32% on a reported basis. Onpattro sales beat the Zacks Consensus Estimate of $45.9 million as well as our model estimate of $46 million.
Amvuttra is FDA-approved for the treatment of adult patients with polyneuropathy of hATTR amyloidosis. The European Commission also approved Amvuttra for treating hATTR amyloidosis in adult patients with stage 1 or 2 polyneuropathy. Recently, label expansion for the drug has also been approved in the United States and the EU for treating cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
Amvuttra generated sales worth $492 million in the second quarter, up 114% on a reported basis. The uptake for the product has been encouraging, with new patients starting treatment as well as several patients switching from Onpattro. The expanded label is also boosting sales. Amvuttra sales easily beat the Zacks Consensus Estimate of $365.4 million as well as our model estimate of $330.7 million.
Givlaari, approved for the treatment of acute hepatic porphyria, recorded sales of $80.8 million, reflecting a year-over-year increase of 30% on a reported basis. Givlaari sales beat the Zacks Consensus Estimate of $72.6 million and our model estimate of $73.1 million. Oxlumo recorded global net product revenues of $46.9 million in the reported quarter, up 15% year over year on a reported basis. Oxlumo sales marginally beat the Zacks Consensus Estimate of $46.6 million as well as our estimate of $43.5 million.
Year to date, ALNY stock has soared 66.7% compared with the industry’s 1.5% rise.
Image Source: Zacks Investment Research
Adjusted research and development (R&D) expenses gained 11% year over year to $274.1 million. R&D expenses accounted for costs associated with the startup activities for a phase III cardiovascular outcomes study, which will evaluate zilebesiran to treat patients with hypertension at high cardiovascular risk, in partnership with Roche. Expenses associated with the recently initiated phase III TRITON-CM study, evaluating nucresiran in patients with ATTR-CM, also contributed to higher R&D costs.
Adjusted selling, general and administrative (SG&A) expenses increased 26% year over year to $261.2 million, primarily due to higher employee compensation costs and increased marketing investment associated with the Amvuttra launch for ATTR-CM.
Cash, cash equivalents and marketable securities as of June 30, 2025, amounted to $2.86 billion compared with $2.63 billion recorded as of March 31, 2025, with the increase primarily driven by net cash inflows from operating activities and proceeds from the exercise of employee stock options.
ALNY Updates 2025 Net Sales Guidance
Alnylam now expects its net product revenues for Onpattro, Amvuttra, Givlaari and Oxlumo in the range of $2.65-$2.8 billion for 2025, up from the previously guided range of $2.05-$2.25 billion.
The guidance for net revenues from collaborations and royalties is maintained in the range of $650-$750 million. Adjusted R&D and SG&A expenses are expected to remain in the band of $2.1-$2.2 billion.
Alnylam Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
ALNY’s Ongoing Collaboration Agreements
Alnylam, in collaboration with Regeneron, is advancing cemdisiran, an investigational RNAi therapeutic for the treatment of complement-mediated diseases. The agreement regarding cemdisiran underwent a modification last year. Per the modified agreement, Alnylam granted exclusive rights to Regeneron to develop cemdisiran as monotherapy and in combination with anti-C5 antibodies for complement-mediated indications.
ALNY regained full global development and commercialization rights to mivelsiran in all indications in 2024, after Regeneron opted out of further co-development and co-commercialization of mivelsiran in development for cerebral amyloid angiopathy and Alzheimer's disease. However, Regeneron will be eligible to receive low double-digit royalties on sales of mivelsiran, if approved.
Alnylam, in collaboration with Roche, is developing zilebesiran in a mid-stage study (KARDIA-3) to treat hypertension. ALNY and RHHBY also plan to initiate a phase III cardiovascular outcomes study for the candidate by the end of 2025 for the same indication.
Alnylam has granted Novartis exclusive global rights to manufacture and commercialize RNAi therapeutics targeting PCSK9, including Leqvio (inclisiran), for hypercholesterolemia and other diseases. The FDA has approved Leqvio for several heart disease indications alongside diet and statins. As of June 2025, Leqvio is approved in more than 106 countries, with ongoing late-stage studies for further label expansion.
Our Take
Alnylam reported better-than-expected results in the second quarter of 2025, beating earnings and revenue estimates. The year-over-year increase in revenues has been mainly fueled by growing Amvuttra sales as a result of increased patient demand. The recent label expansion of the drug for the ATTR-CM indication in the United States and the EU has further expanded the eligible patient population for the drug, which is boosting sales and is expected to continue to do so in the quarters ahead. Sales of other products, Givlaari and Oxlumo, are also contributing to the top line.
ALNY’s Zacks Rank
Alnylam currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up

The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 1. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This biopharmaceutical company is expected to post quarterly earnings of $8.15 per share in its upcoming report, which represents a year-over-year change of -29.5%.
Revenues are expected to be $3.34 billion, down 5.7% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 6.49% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Regeneron?
For Regeneron, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +7.62%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that Regeneron will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Regeneron would post earnings of $8.43 per share when it actually produced earnings of $8.22, delivering a surprise of -2.49%.
Over the last four quarters, the company has beaten consensus EPS estimates three times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Regeneron appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected Results
Alnylam Pharmaceuticals (ALNY), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report loss per share of $0.03 for the quarter ended June 2025. This estimate points to a year-over-year change of -105.4%. Revenues for the quarter are expected to be $671.11 million, up 1.7% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Alnylam has been revised 63% up to the current level. Nevertheless, the company now has an Earnings ESP of +831.25%, reflecting a higher Most Accurate Estimate.
When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Alnylam will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Should You Invest in Regeneron Pharmaceuticals, Inc. (REGN)?
Before you invest in Regeneron Pharmaceuticals, Inc. (REGN), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Written by Keith Speights, David Jagielski, Prosper Junior Bakiny for The Motley Fool->
Many investors love the "big mo." That's short for "big momentum." Stocks that are on a roll often keep the good times going.
Three Fool.com contributors think they've found high-flying biotech stocks that could soar even more. Here's why they picked Alnylam Pharmaceuticals (NASDAQ: ALNY), Axsome Therapeutics (NASDAQ: AXSM), and Summit Therapeutics (NASDAQ: SMMT).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Exciting times for this biotech innovator
Keith Speights (Alnylam Pharmaceuticals): In her comments during Alnylam Pharmaceuticals' first-quarter update, CEO Yvonne Greenstreet said, "2025 is off to a remarkable start." She was exactly right.
Alnylam's share price has jumped close to 23% year to date. The stock has almost doubled over the last 12 months. Alnylam reported 28% year-over-year revenue growth in Q1, driven largely by its U.S. transthyretin amyloidosis franchise.
On March 20, 2025, the U.S. Food and Drug Administration (FDA) approved Alnylam's Amvuttra in treating cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Only two days earlier, Sanofi won FDA approval of Qfitlia for treating hemophilia. Alnylam licensed the drug to Sanofi and stands to receive tiered royalties of 10% to 15% on all sales.
Amvuttra captured roughly 70% of new patient starts in Q1 despite only receiving a thumbs-up from the FDA late in the quarter. Alnylam expects the drug's U.S. momentum to build in the second half of 2025. It also hopes to win approvals in Japan in Q2 and in the European Union in Q3. Analysts think Amvuttra will become a huge blockbuster drug for Alnylam, with peak annual sales in the ballpark of $7.9 billion by 2035.
More good news could be on the way. Alnylam plans to announce results from a phase 2 study evaluating zilebesiran in treating hypertension later this year. The company hopes to advance the drug to phase 3 testing in the second half of 2025. It also intends to move nucresiran into late-stage testing as a treatment for ATTR-CM within the next month or so.
Wall Street is largely bullish about this stock, with 24 of the 33 analysts surveyed by LSEG rating it as a "buy" or a "strong buy." I agree with this optimism. Alnylam should have plenty of room to run.
There is plenty of upside left for this stock
Prosper Junior Bakiny (Axsome Therapeutics): Share prices of Axsome Therapeutics, a mid-cap biotech, are up by 234% in the past three years thanks to solid clinical and regulatory progress. Notably, the company earned FDA approval for Auvelity, a therapy for major depressive disorder, in 2022. Then there is Symbravo, a migraine treatment, that earned the nod in January.
Axsome Therapeutics' top line is growing rapidly, with Auvelity leading the charge. In the first quarter, the company's revenue came in at $121.5 million, up 62% year over year.
The good news is that there are more catalysts ahead that could jolt the stock price. Axsome Therapeutics has a large late-stage pipeline that should lead to more approvals and label expansions. For example, AXS-05, the generic name for Auvelity, aced late-stage clinical trials in treating Alzheimer's disease agitation. The company will soon seek approval for the medicine in this indication.
The company is also inching closer to a regulatory submission for AXS-12, an investigational medicine for cataplexy in narcolepsy patients. That only scratches the surface of Axsome Therapeutics' pipeline. The drugmaker should see over half a dozen late-stage clinical trial readouts, regulatory submissions, or approvals in the next two years.
And as the company makes progress, its financial results will improve. Axsome Therapeutics is slowly establishing itself as a notable player in the biotech industry. So, despite its shares crushing the market over the past three years, it's not too late to buy the stock.
This stock may not have reached its peak just yet
David Jagielski (Summit Therapeutics): After soaring a staggering 440% in the past 12 months, you might think that Summit Therapeutics stock might be running out of steam. But while its near-$18 billion valuation is high, especially for a company which doesn't even have an approved product yet, it's possible that it could still go higher.
Everything hinges on whether its cancer treatment, ivonescimab, is in fact the real deal or not. In a recent clinical trial, ivonescimab showed that it was able to reduce the risk of death or disease progression in patients with metastatic or locally advanced non-small cell lung cancer by 49%, when compared to Merck's top-selling cancer drug, Keytruda.
The problem, and what may be limiting the healthcare stock from even more gains right now, is that the study was based in China. For regulators in the U.S. to approve the drug, they'll likely want to see a more diverse study, which can confirm its effectiveness.
Summit is working on global trials involving ivonescimab, and if the data proves to be encouraging, then it might not be a surprise to see the stock surge even higher in value. Keytruda has generated tens of billions of dollars for Merck over the years, and if Summit is sitting on a potentially better drug than that, it's easy to see why investors may still have a lot of reasons to remain bullish.
Investors, however, should tread carefully because there is considerable risk with the stock, as the business isn't generating revenue and there's not much else to fall back on right now besides ivonescimab; if clinical trial results prove to be underwhelming from a wider and more diverse group of participants, then a significant sell-off could ensue.
Should you invest $1,000 in Alnylam Pharmaceuticals right now?
Before you buy stock in Alnylam Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alnylam Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $640,662!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $814,127!*
Now, it’s worth noting Stock Advisor’s total average return is 963% — a market-crushing outperformance compared to 168% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
David Jagielski has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alnylam Pharmaceuticals, Axsome Therapeutics, Merck, and Summit Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

3 High-Flying Stocks That Could Soar Even More

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $288.7 million dollar outflow -- that's a 5.9% decrease week over week (from 62,450,000 to 58,750,000). Among the largest underlying components of XBI, in trading today EXACT Sciences Corp. (Symbol: EXAS) is down about 0.4%, Alnylam Pharmaceuticals Inc (Symbol: ALNY) is down about 0.9%, and Natera Inc (Symbol: NTRA) is lower by about 6.1%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $66.66 per share, with $105.47 as the 52 week high point — that compares with a last trade of $78.34. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Cheap Industrials Shares
BTZ Average Annual Return
Cintas MACD
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

XBI, EXAS, ALNY, NTRA: Large Outflows Detected at ETF

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. This momentum model looks for a combination of fundamental momentum and price momentum.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
FUNDAMENTAL MOMENTUM:
PASS
TWELVE MINUS ONE MOMENTUM:
PASS
FINAL RANK:
PASS
Detailed Analysis of ALNYLAM PHARMACEUTICALS, INC.
ALNY Guru Analysis
ALNY Fundamental Analysis
More Information on Dashan Huang
Dashan Huang Portfolio
About Dashan Huang: Dashan Huang is an Assistant Professor of Finance at the Lee Kong Chian School of Business at Singapore Management University. His paper "Twin Momentum" looked at combining traditional price momentum with improving fundamentals to generate market outperformance. In the paper, he identified seven fundamental variables (earnings, return on equity, return on assets, accrual operating profitability to equity, cash operating profitability to assets, gross profit to assets and net payout ratio) that he combined into a single fundamental momentum measure. He showed that stocks in the top 20% of the universe according to that measure outperformed the market going forward. When he combined that measure with price momentum, he was able to double its outperformance.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats 2025
Wide Moat Stocks
Recession Proof Stocks
High Insider Ownership Stocks
Factor-Based Stock Portfolios
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Validea Detailed Fundamental Analysis - ALNY

My definition of a high yield is any yield at least twice the level of the S&P 500's yield. The threshold is currently around 2.56%. An ultra-high yield, in my view, is one that's four times higher than the S&P 500's yield. To reach that lofty level, a yield would need to be at least 5.12%.
Many income investors would be happy to receive yields of over 5.12%. But what if you could get a yield of roughly triple that amount? Believe it or not, you can. These three funds offer sky-high yields of 15% or more -- and they even trade at a discount.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
1. abrdn Life Sciences Investors
The abrdn Life Sciences Investors (NYSE: HQL) is a closed-end fund (CEF) that, as its name indicates, invests primarily in life sciences companies. Aberdeen Investments launched this fund in May 1992, so it has a long track record.
As of March 31, 2025, the abrdn Life Sciences Investors fund owned 136 stocks. Its top positions include Regeneron Pharmaceuticals, Amgen, Gilead Sciences, Vertex Pharmaceuticals, and Alnylam Pharmaceuticals.
This CEF currently pays a distribution yield of 15.06%. It's also available at a discount of 9.36% below the net asset value (NAV). The abrdn Life Sciences Investors fund uses relatively low leverage, with its effective leverage ratio at only 2.26%. The fund's annual expense ratio of 1.36% is also relatively low for a CEF.
Since its inception, the abrdn Life Sciences Investors fund has delivered an average annual total return (based on its market price) of 8.12%. Over the last five years, its average annual total return is 6.84%. The CEF clearly can't pay distribution yields at the current levels with those kinds of returns without eating into investors' paid-in capital.
2. BlackRock Capital Allocation Term Trust
If you're looking for a jaw-dropping yield, check out the BlackRock Capital Allocation Term Trust (NYSE: BCAT). This CEF, managed by huge investment company BlackRock, offers a distribution yield of (you might want to sit down for this)... 23.88%. Also, the fund trades at a 6.04% discount to its NAV. And it doesn't use any leverage. Too good to be true? No, although there is a catch that we'll discuss shortly.
The BlackRock Capital Allocation Term Trust invests in both equity and debt securities. Its portfolio currently includes 1,641 holdings. Top equity positions include Microsoft, Amazon, Google parent Alphabet, Mastercard, and Marsh & McLennan.
How does this CEF pay such a super-high yield? It sells options and uses the premiums to boost its distributions. With the stock market's volatility unusually high, the BlackRock Capital Allocation Term Trust is making more money from selling options than it normally does.
Now for some important details. The BlackRock Capital Allocation Term Trust has a 12-year limited term. This means that 12 years after its inception (which was on Sept. 28, 2020), the fund will liquidate its holdings and return the money to shareholders. However, the CEF has the option of converting to a perpetual fund before its term ends.
Also, the fund's average annual total return since inception is only 4.81%. The BlackRock Capital Allocation Term Trust can't pay distributions at the current level without its NAV declining.
3. BlackRock Science and Technology Term Trust
Another CEF managed by BlackRock pays a distribution yield of exactly 15% right now. I'm referring to the BlackRock Science and Technology Term Trust (NYSE: BSTZ). This fund trades at a 7.17% discount to its NAV.
This CEF shares two important things in common with the other BlackRock fund on our list. First, it has a 12-year limited term but could convert to a perpetual fund. Since the BlackRock Science and Technology Term Trust launched on June 26, 2019, the fund will liquidate its assets in another six or so years unless it converts to perpetual. Second, the CEF sells options to generate premiums to increase its distributions.
As you might have guessed, this CEF focuses on investing in science and technology companies. It currently owns 293 stocks, with top positions including Project Debussy (BlackRock's private investment in software company Databricks), Nvidia, Project Picasso (BlackRock's private investment in quantum computer company PsiQuantum), and Spotify Technology.
Is there a big fly in the ointment with this ultra-high-yielding fund? Unfortunately, yes. The BlackRock Science and Technology Term Trust has delivered an average annual total return of 8.27%. This isn't bad, but it's not nearly enough to fund the distributions at current levels without eroding an initial investment.
Should you invest $1,000 in BlackRock Capital Allocation Term Trust right now?
Before you buy stock in BlackRock Capital Allocation Term Trust, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BlackRock Capital Allocation Term Trust wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $598,818!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $666,416!*
Now, it’s worth noting Stock Advisor’s total average return is 872% — a market-crushing outperformance compared to 160% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of April 28, 2025
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Keith Speights has positions in Alphabet, Amazon, Mastercard, Microsoft, and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Alnylam Pharmaceuticals, Alphabet, Amazon, Amgen, Gilead Sciences, Mastercard, Microsoft, Nvidia, Regeneron Pharmaceuticals, Spotify Technology, and Vertex Pharmaceuticals. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount

Investors in Alnylam Pharmaceuticals Inc (Symbol: ALNY) saw new options become available this week, for the May 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALNY options chain for the new May 16th contracts and identified one put and one call contract of particular interest.
The put contract at the $210.00 strike price has a current bid of $10.30. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $210.00, but will also collect the premium, putting the cost basis of the shares at $199.70 (before broker commissions). To an investor already interested in purchasing shares of ALNY, that could represent an attractive alternative to paying $236.24/share today.
Because the $210.00 strike represents an approximate 11% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 67%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 4.90% return on the cash commitment, or 45.90% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Alnylam Pharmaceuticals Inc, and highlighting in green where the $210.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $240.00 strike price has a current bid of $10.80. If an investor was to purchase shares of ALNY stock at the current price level of $236.24/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $240.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 6.16% if the stock gets called away at the May 16th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ALNY shares really soar, which is why looking at the trailing twelve month trading history for Alnylam Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ALNY's trailing twelve month trading history, with the $240.00 strike highlighted in red:
Considering the fact that the $240.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 59%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 4.57% boost of extra return to the investor, or 42.79% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 62%, while the implied volatility in the call contract example is 60%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 250 trading day closing values as well as today's price of $236.24) to be 50%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
Also see:
NH YTD Return
TUSA YTD Return
BCR Insider Buying
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

First Week of ALNY May 16th Options Trading

Friday, April 4, 2025
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), UnitedHealth Group Inc. (UNH) and Toyota Motor Corp. (TM), as well as a micro-cap stock Perma-Pipe International Holdings, Inc. (PPIH). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-Markets Down Another -2% on Good Jobs Report
Today's Featured Research Reports
Broadcom’s shares have outperformed the Zacks Electronics - Semiconductors industry over the past year (+15.9% vs. -8.4%). The company is benefiting from strong demand for its networking products and custom AI accelerators (XPUs) as witnessed in its first-quarter fiscal 2025 report. Strong demand for Broadcom’s application-specific integrated chips (ASICs), designed to support AI and machine learning, aids top-line growth.
Broadcom expects second-quarter fiscal 2025 AI revenues to jump 44% year over year to $4.4 billion. The acquisition of VMware has benefited Infrastructure software solutions. As of Q1, roughly 70% of Broadcom’s largest 10,000 customers have adopted VMware Cloud Foundation.
Broadcom’s expanding AI portfolio, along with a rich partner base, reflects solid top-line growth potential. However, gross margin in its fiscal Q2 is expected to contract sequentially on unfavorable revenue and product mix. High debt level is a headwind.
(You can read the full research report on Broadcom here >>>)
Shares of UnitedHealth have outperformed the Zacks Medical - HMOs industry over the past year (+20.5% vs. +12.3%). The company’s top line remains poised for growth on the back of a strong market position, new deals, renewed agreements and expansion of service offerings. UnitedHealth’s solid health services segment provides diversification benefits. Its Government business remains well-poised for growth in the future.
Adjusted net earnings per share are anticipated to be in the $29.50-$30 range in 2025. A sturdy balance sheet enables investments and prudent deployment of capital via buybacks and dividend payments.
However, declining membership in its global business continues to be a concern. High operating costs due to rising medical expenses are hurting margins. The Zacks analyst expects medical costs to jump over 14% YoY in 2025. A debt-laden balance sheet induces an increase in interest expenses.
(You can read the full research report on UnitedHealth here >>>)
Toyota Motor’s shares have declined -30.1% over the past year against the Zacks Automotive - Foreign industry’s decline of -32.9%. The company’s significant investments in human capital and expansion initiatives are expected to weigh on operating profits this fiscal year. Elevated R&D expenditures on advanced technologies and alternative fuels support long-term innovation, but may constrain near-term margins. Rising debt levels also pose financial challenges. The stock warrants a cautious stance now.
Nevertheless, the surge in hybrid adoption is driving Toyota’s sales, supported by strategic initiatives to accelerate growth and enhance profitability. The company is working to restore production to normal levels.
While prioritizing hybrids, Toyota remains committed to the BEV market, with plans to introduce solid-state batteries that promise extended range and lower production costs. Investor-friendly moves further bolster optimism.
(You can read the full research report on Toyota Motor here >>>)
Shares of Perma-Pipe International have outperformed the Zacks Steel - Pipe and Tube industry over the past year (+43.3% vs. +1.3%). This microcap company with market capitalization of $92.40 million have backlog which grew 33% to over $100 million by November, reflecting strong demand in key markets like oil and gas and district energy.
Geographic diversification, including $61 million in recent contracts across MENA and the Americas, reduces regional risks while positioning the company for growth in energy and infrastructure. Its focus on high-growth markets aligns with robust infrastructure development, supported by proprietary technologies like the XTRU-THERM insulation system, bolstering market leadership.
The company’s tailored solutions cater to high-margin sectors, ensuring operational resilience. Long-term demand is underpinned by global steel pipe market growth, fueled by investments in infrastructure and urbanization. However, exposure to cyclical markets, intense competition, geopolitical risks and regulatory compliance costs present challenges.
(You can read the full research report on Perma-Pipe International here >>>)
Other noteworthy reports we are featuring today include Constellation Energy Corp. (CEG), Alnylam Pharmaceuticals, Inc. (ALNY) and LPL Financial Holdings Inc. (LPLA).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Strong Demand for Networking Products Aids Broadcom (AVGO)
Solid Optum Unit Drives UnitedHealth (UNH), High Costs Hurt
Surge in Hybrid Adoption Aids Toyota (TM) Amid High Expenses
Featured Reports
Focus on Renewable Energy Aid Constellation Energy (CEG)
Per the Zacks analyst, Constellation Energy gains from expansion of renewable portfolio. Its position as an industry leader in the safe operation of nuclear plants helps it increase its nuclear output
Amvuttra & Givlaari Boosts Alnylam (ALNY), Pipeline Holds Promise
Per the Zacks Analyst, Amvuttra and Givlaari sales are expected to continue to boost Alnylam's sales. Its existing collaboration agreements to develop pipeline candidates are also progressing well.
Buyouts to Support LPL Financial (LPLA) Amid Rising Expenses
Per the Zacks analyst, buyouts such as Commonwealth Financial, a solid balance sheet, and advisor productivity will likely aid LPL Financial. Yet, high costs and volatile commission revenues are woes.
Hormel Foods (HRL) Benefits from Solid Foodservice Segment
Per the Zacks analyst, Hormel Foods is benefiting from strength in the Foodservice business. During the first quarter of fiscal 2025, Foodservice sales increased 2% to $930.2 million.
Defense Orders Drive Huntington Ingalls (HII), Amid Labor Shortage
Per the Zacks analyst, Huntington Ingalls is likely to benefit from increasing defense orders from the Pentagon and US allies. Yet labor shortage result in delays and likely impact operating results.
Lamb Weston's (LW) Top Line Gains From Robust Volume Growth
Per the Zacks analyst, Lamb Weston's fiscal third-quarter sales growth was backed by higher volumes in all units. Volume is expected to remain strong, which is likely to fuel fiscal 2025 sales.
Strategic Acquisitions Buoy Northern Oil and Gas (NOG)
The Zacks analyst notes that Northern Oil and Gas' acquisitions in the Permian and Uinta Basins boost growth by expanding assets and production, but oil price volatility remains a key risk.
New Upgrades
Strength Across Outdoor & Fitness Segments Aid Garmin (GRMN)
Per the Zacks analyst, Garmin is riding on solid demand for adventure watches and advanced wearables which is driving the performance of its Outdoor and Fitness segments.
Veeva Systems (VEEV) Gains on Solid R&D, Strategic Alliances
Per the Zacks analyst, Veeva Systems is gaining from strong customer adoption and strategic alliances. Innovation, a solid product portfolio, and a debt-free balance sheet are also fueling growth.
Solid Demand, Pricing Actions Aid Carpenter Technology (CRS)
Per the Zacks analyst, Carpenter Technology is gaining from strong demand across its end-use markets. Cost-reduction initiatives and efforts to preserve liquidity are also driving growth.
New Downgrades
Schneider (SNDR) is Hurt by Lower Brokerage Revenues & Volumes
The Zacks Analyst is worried about the fact that lower Network volumes and lower brokerage revenue per order hurt Schneider's top line.
Debt Load and Stiff Competition Weigh on America Movil (AMX)
Per the Zacks analyst, America Movil's faces stiff competition from other telecom giants along with a highly leveraged balance sheet remains a concern.
Mohawk (MHK) is Hurting from Macro Headwinds & High Costs
Per the Zacks analyst, Mohawk's prospects are hurting from the ongoing market uncertainties and an elevated cost environment. Also, housing market weakness adds to the headwinds.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
Toyota Motor Corporation (TM) : Free Stock Analysis Report
Constellation Energy Corporation (CEG) : Free Stock Analysis Report
Broadcom Inc. (AVGO) : Free Stock Analysis Report
LPL Financial Holdings Inc. (LPLA) : Free Stock Analysis Report
Perma-Pipe International Holdings, Inc. (PPIH): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Analyst Reports for Broadcom, UnitedHealth & Toyota Motor

The Invesco NASDAQ Next Gen 100 ETF (QQQJ) was launched on 10/13/2020, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Growth segment of the US equity market.
The fund is sponsored by Invesco. It has amassed assets over $591.14 million, making it one of the average sized ETFs attempting to match the Large Cap Growth segment of the US equity market.
Why Large Cap Growth
Companies that find themselves in the large cap category typically have a market capitalization above $10 billion. They tend to be stable companies with predictable cash flows and are usually less volatile than mid and small cap companies.
Growth stocks have higher than average sales and earnings growth rates. While these are expected to grow faster than the broader market, they also have higher valuations. Additionally, growth stocks have a greater level of risk associated with them. Compared to value stocks, growth stocks are a safer bet in a strong bull market, but don't perform as strongly in almost all other financial environments.
Costs
Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive counterparts if all other fundamentals are the same.
Annual operating expenses for this ETF are 0.15%, making it one of the least expensive products in the space.
It has a 12-month trailing dividend yield of 0.73%.
Sector Exposure and Top Holdings
While ETFs offer diversified exposure, which minimizes single stock risk, a deep look into a fund's holdings is a valuable exercise. And, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation to the Information Technology sector--about 30% of the portfolio. Healthcare and Industrials round out the top three.
Looking at individual holdings, Alnylam Pharmaceuticals Inc (ALNY) accounts for about 1.98% of total assets, followed by Ebay Inc (EBAY) and United Airlines Holdings Inc (UAL).
The top 10 holdings account for about 16.77% of total assets under management.
Performance and Risk
QQQJ seeks to match the performance of the NASDAQ NEXT GENERATION 100 INDEX before fees and expenses. The NASDAQ Next Generation 100 Index comprises of securities of the next generation of Nasdaq-listed non-financial companies; that is, the largest 100 Nasdaq-listed companies outside of the NASDAQ-100 Index.
The ETF has lost about -5.75% so far this year and was up about 1.50% in the last one year (as of 04/02/2025). In the past 52-week period, it has traded between $26.60 and $32.91.
The ETF has a beta of 1.13 and standard deviation of 21.57% for the trailing three-year period. With about 110 holdings, it effectively diversifies company-specific risk.
Alternatives
Invesco NASDAQ Next Gen 100 ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, QQQJ is a sufficient option for those seeking exposure to the Style Box - Large Cap Growth area of the market. Investors might also want to consider some other ETF options in the space.
The Vanguard Growth ETF (VUG) and the Invesco QQQ (QQQ) track a similar index. While Vanguard Growth ETF has $142.93 billion in assets, Invesco QQQ has $298.90 billion. VUG has an expense ratio of 0.04% and QQQ charges 0.20%.
Bottom-Line
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.
Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report
United Airlines Holdings Inc (UAL) : Free Stock Analysis Report
eBay Inc. (EBAY) : Free Stock Analysis Report
Invesco QQQ (QQQ): ETF Research Reports
Vanguard Growth ETF (VUG): ETF Research Reports
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?

In trading on Tuesday, shares of Alnylam Pharmaceuticals Inc (Symbol: ALNY) crossed below their 200 day moving average of $256.13, changing hands as low as $255.13 per share. Alnylam Pharmaceuticals Inc shares are currently trading down about 5.3% on the day. The chart below shows the one year performance of ALNY shares, versus its 200 day moving average:
Looking at the chart above, ALNY's low point in its 52 week range is $141.975 per share, with $304.39 as the 52 week high point — that compares with a last trade of $255.76.
Click here to find out which 9 other stocks recently crossed below their 200 day moving average »
Also see:
Real Estate Dividend Stocks
MIB Historical Stock Prices
SKS Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Alnylam Pharmaceuticals, Inc.

Sign up and get access to the forecasts, "shares 360" and dividend history